Synonyms: MPDL3280A
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | PD-1/PD-L1 interaction | PD-1 | PD-L1 | PD-1/PD-L1 | Others |
|---|---|---|---|---|---|---|
| GS-4224 | 0 | |||||
| INCB086550 | 1 | |||||
| BMS-1001 | 0 | |||||
| BMS-1166 | 8 | |||||
| PD-1/PD-L1 Inhibitor 3 | 13 | |||||
| BMS-1 | 13 | |||||
| BMS-202 | 26 | |||||
| CA-170 (AUPM-170) | 0 | |||||
| SR 0987 | 1 | IL17,RORγt | ||||
| Spartalizumab (anti-PD-1) | 3 | |||||
| Camrelizumab (anti-PD-1) | 2 | |||||
| AUNP-12 | 3 |
| Description |
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
|
|---|---|
| Features |
Human IgG1
|
| Targets/IC50/Ki |
hPD-L1
(Cell-free assay) 0.4 nM(Kd)
|
| In vitro |
Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models. |
| Cell Research |
A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations. |
| In vivo |
when dual drug–loaded, core-shell nanoparticles (DLTPT) is used in combination with anti PD-L1, the tumor growth is inhibited, which induced immune response against tumor metastasis. |
| Animal Research |
Animal Models: 4T1 tumor–bearing BALB/c mice |
References |
|
| CAS No. | 1380723-44-3 |
|---|---|
| Isotype | Human IgG1 |
| Source | CHO cells |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
How to store the antibody?
Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.